Refractoriness to platelet transfusions
. | PCT . | Control . | P . |
|---|---|---|---|
| ITT population, n | 318 | 327 | — |
| Any refractory episode, %* | 21.4 | 7.0 | < .001 |
| Any transfusion with CCI less than 5 × 10, % | 27.4 | 12.7 | < .001 |
| Refractory subset of patients, n | 68 | 23 | — |
| Single episode of refractoriness, % | 57 | 65 | .63 |
| Refractory to end of study, % | 6 | 9 | .64 |
| Immunologic refractoriness† | |||
| LCA and/or platelet alloantibody, % | 22 | 44 | .06 |
| Lymphocytotoxic antibodies, % | 15 | 39 | .02 |
| Platelet specific alloantibodies, % | 12 | 10 | 1.00 |
| Antibody to amotosalen neoantigens | 0 | 0 | — |
. | PCT . | Control . | P . |
|---|---|---|---|
| ITT population, n | 318 | 327 | — |
| Any refractory episode, %* | 21.4 | 7.0 | < .001 |
| Any transfusion with CCI less than 5 × 10, % | 27.4 | 12.7 | < .001 |
| Refractory subset of patients, n | 68 | 23 | — |
| Single episode of refractoriness, % | 57 | 65 | .63 |
| Refractory to end of study, % | 6 | 9 | .64 |
| Immunologic refractoriness† | |||
| LCA and/or platelet alloantibody, % | 22 | 44 | .06 |
| Lymphocytotoxic antibodies, % | 15 | 39 | .02 |
| Platelet specific alloantibodies, % | 12 | 10 | 1.00 |
| Antibody to amotosalen neoantigens | 0 | 0 | — |
— indicates not applicable.
Episode is 2 consecutive platelet transfusions with 1-hour CCI < 5 × 103
Immunologic refractoriness, defined as the presence of LCA (> 20% PRA), platelet alloantibodies, and/or antibody to potential amotosalen neoantigens in the presence of 2 consecutive 1-hour CCI less than 5 × 103